Grant Support: The American Cancer Society (RSG-04-053-01-GMC), National Institutes of Health RO1 [CA-127892-01A], National Institutes of Health RO3 [CA119309].
1755-148X/asset/olbannercenter.gif?v=1&s=72f30e3842b97b67d7bc25d75c3ceea43fce9409)
You have free access to this content
Use of liposomes as drug delivery vehicles for treatment of melanoma
Article first published online: 26 MAY 2009
DOI: 10.1111/j.1755-148X.2009.00581.x
© 2009 John Wiley & Sons A/S
Additional Information
How to Cite
Tran, M. A., Watts, R. J. and Robertson, G. P. (2009), Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell & Melanoma Research, 22: 388–399. doi: 10.1111/j.1755-148X.2009.00581.x
Publication History
- Issue published online: 13 JUL 2009
- Article first published online: 26 MAY 2009
- PUBLICATION DATA Received 9 April 2009, revised and accepted for publication 8 May 2009
- Abstract
- Article
- References
- Cited By
Keywords:
- Melanoma;
- antibodies;
- siRNA;
- liposomes;
- chemotherapy
Summary
Melanoma is a progressive disease that claims many lives each year due to lack of therapeutics effective for the long-term treatment of patients. Currently, the best treatment option is early detection followed by surgical removal. Better melanoma therapies that are effectively delivered to tumors with minimal toxicity for patients are urgently needed. Nanotechnologies provide one approach to encapsulate therapeutic agents leading to improvements in circulation time, enhanced tumor uptake, avoidance of the reticulo-endothelial system, and minimization of toxicity. Liposomes in particular are a promising nanotechnology that can be used for more effective delivery of therapeutic agents to treat melanoma. Liposomes delivering chemotherapies, siRNA, asODNs, DNA, and radioactive particles are just some of the promising new nanotechnology based therapies under development for the treatment of melanoma that are discussed in this review.